
|Articles|November 1, 2003
New drug targets considered for erectile dysfunction
Author(s)Robert H. Carlson
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
4
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
5






